Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis

1 Jan 2021

Abstract excerpt

Background: Intravenous immunoglobulin (IVIG) has been commonly used to treat myasthenia gravis exacerbation, but is still ineffective in nearly 30% of patients. A variable number of tandem repeat (VNTR) polymorphism in the FCGRT gene has been found to reduce the efficiency of IgG biologics. However, whether the polymorphism influences the efficacy of IVIG in generalized myasthenia gravis (MG) patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Myasthenia Gravis and Thymoma
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33552238
DOI: 10.1177/1756286420986747

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravisPMID 33552238Read ↗

Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients.Semantic proximity Read ↗

Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults.Semantic proximity Read ↗

FcgammaRIIA and FcgammaRIIIB polymorphisms in myasthenia gravis.Semantic proximity Read ↗

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of its Pharmacological Profile, Clinical Utility, and Expanding ApplicationsSemantic proximity Read ↗

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.Semantic proximity Read ↗

GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis.Semantic proximity Read ↗

Early Versus Delayed Add-on Therapy in Generalized Myasthenia Gravis: A Multicenter Real-World Cohort StudySemantic proximity Read ↗

FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.Semantic proximity Read ↗

Enhanced serum immunoglobulin G clearance in myotonic dystrophy-associated hypogammaglobulinemia: a case series and review of the literature.Semantic proximity Read ↗

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.Semantic proximity Read ↗

β2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality.Semantic proximity Read ↗

Clinical value of soluble IgG Fc receptor type III in plasma from patients with chronic idiopathic neutropenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.